Skip to main content

Table 2 Patient characteristics of “TNFi success” and “failing TNFi” cohorts

From: Unmet needs in ankylosing spondylitis patients receiving tumour necrosis factor inhibitor therapy; results from a large multinational real-world study

 

All

North America

LatAm

EU5

APAC

T&ME

Group

TNFi Success

(n = 1275)

Failing TNFi

(n = 232)

TNFi Success

(n = 270)

Failing TNFi

(n = 56)

TNFi Success

(n = 73)

Failing TNFi(n = 15)

TNFi Success

(n = 733)

Failing TNFi

(n = 103)

TNFi Success

(n = 112)

Failing TNFi

(n = 44)

TNFi Success

(n = 87)

Failing TNFi

(n = 14)

Age, years

 Median

43.0

45.0

45.0

47.0

41.0

45.0

44.0

49.0

40.0

36.5

38.0

34.0

 Mean (SD)

43.8 (12.1)

45.7 (13.2)

45.5 (13.4)

47.8 (12.0)

42.5 (12.0)

44.8 (6.3)

44.6 (11.8)

48.8 (13.8)

40.6 (12.4)

39.3 (13.5)

37.8 (6.9)

35.9 (4.7)

P

0.0516

0.1996

0.0956

0.0035

0.5310

0.2808

Male, n (%)

1009 (79.1)

165 (71.1)

220 (81.5)

42 (75.0)

50 (68.5)

9 (60.0)

582 (79.4)

66 (64.1)

90 (80.4)

36 (81.8)

67 (77.0)

12 (85.7)

P

0.0097

0.2708

0.5554

0.0009

1

0.7287

BMI, kg/m2

 Median

25.3

25.2

25.9

27.0

25.6

25.0

25.2

25.6

23.4

22.9

25.6

25.7

 Mean (SD)

25.7 (3.8)

26.0 (4.7)

26.5 (4.1)

27.8 (4.9)

25.9 (3.2)

25.2 (5.0)

25.5 (3.4)

26.2 (4.5)

23.8 (4.3)

23.4 (4.0)

26.8 (4.7)

26.5 (4.0)

P

0.8563

0.0418

0.3570

0.2809

0.4638

0.9881

Current Smoker

 n, %

381 (29.9)

81 (34.9)

37 (13.7)

17 (30.4)

7 (9.6)

2 (13.3)

252 (34.4)

38 (36.9)

29 (25.9)

17 (38.6)

56 (64.4)

7 (50.0)

P

0.1412

0.0049

0.6471

0.6586

0.1235

0.3761

Time since symptom onset (years)

 n

1110

196

238

43

73

15

611

86

103

38

85

14

 Median

7.0

8.0

8.0

10.0

5.0

3.0

9.0

10.0

8.0

5.0

2.3

2.0

 Mean (SD)

10.4 (9.2)

11.7 (11.2)

12.0 (10.8)

11.6 (9.1)

8.9 (9.7)

8.3 (10.9)

10.8 (8.8)

14.5 (12.6)

10.8 (8.4)

9.9 (10.4)

3.0 (2.1)

3.3 (2.7)

P

0.6081

0.7041

0.2977

0.0554

0.1978

0.8485

Time since diagnosis (years)

 n

1170

209

253

51

72

15

659

91

103

38

83

14

 Median

5.0

5.0

5.0

5.0

3.0

2.0

5.0

6.0

5.0

3.0

1.2

1.0

 Mean (SD)

7.2 (7.2)

8.4 (9.6)

7.9 (8.1)

9.0 (9.3)

5.9 (6.4)

6.6 (10.5)

7.8 (7.0)

10 (10.3)

7.2 (6.7)

6.7 (8.5)

1.7 (1.8)

2.1 (2.2)

P

0.7489

0.2647

0.3055

0.1946

0.0886

0.7456

HLA-B27 + ve

 n

919

145

204

35

63

12

542

69

65

22

45

7

 n, %

809 (88.0)

129 (89.0)

177 (86.8)

32 (91.4)

57 (90.5)

12 (100.0)

484 (89.3)

59 (85.5)

55 (84.6)

20 (90.9)

36 (80.0)

6 (85.7)

P

0.8900

0.5861

0.5811

0.3159

0.7224

1

Current AS symptoms

 n

1275

232

270

56

73

15

733

103

112

44

87

14

 Median

1.0

2.0

2.0

2.5

2.0

1.0

1.0

2.0

1.0

2.0

1.0

2.0

 Mean (SD)

1.8 (1.4)

2.5 (1.7)

2.1 (1.7)

3.1 (2.2)

1.9 (1.4)

1.7 (1.2)

1.6 (1.3)

2.4 (1.6)

1.8 (1.6)

2.3 (1.4)

1.5 (1.5)

1.9 (1.4)

P

< 0.0001

0.0003

0.6424

< 0.0001

0.0203

0.2567

ESR, mm/hr (within 3 months)

 n

780

143

148

36

43

7

438

57

79

29

72

14

 Median

12.0

20.0

14.0

31.5

10.0

12.0

12.0

21.0

10.0

15.0

20.0

32.0

 Mean (SD)

15.1 (11.8)

24.9 (19.3)

17.8 (12.8)

27.4 (19.0)

11.5 (7.8)

11.1 (8.5)

13.8 (11.6)

22.5 (16.3)

13.0 (12.0)

28.4 (26.8)

22.0 (8.8)

28.3 (13.7)

P

< 0.0001

0.0078

0.9551

< 0.0001

0.0035

0.1976

CRP, mg/l (within 3 months)

 n

718

124

116

24

35

4

425

54

74

28

68

14

 Median

2.5

5.0

1.6

3.3

2.0

1.0

3.0

6.0

1.1

3.0

2.6

4.9

 Mean (SD)

4.5 (6.0)

7.2 (9.0)

4.6 (8.2)

7.7 (9.5)

3.2 (4.0)

0.8 (0.5)

4.7 (5.1)

9.8 (11.2)

3.7 (7.5)

3.6 (3.3)

4.2 (5.9)

5.0 (0.9)

P

< 0.0001

0.0167

0.1117

< 0.0001

0.3160

0.0042

  1. Patients were deemed to be failing TNFi after at least 3 months if disease severity had worsened or remained severe, disease activity was unstable or deteroriating, disease was not considered by physician to be controlled, nor treatment a success. Patients not considered to be failing TNFi were considered to be “TNFi success”
  2. Abbreviations: APAC Asia Pacific region, AS ankylosing spondylitis, BMI body mass index, CRP c-reactive protein, ESR erthyrocyte sedimentation rate, EU5 European Union 5, HLA-B27 human leukocyte antigen B27, LatAm Latin America, T&ME Turkey and Middle East, SD standard deviation
Back to article page

BMC Rheumatology

ISSN: 2520-1026

Contact us